News | October 17, 2007

XTent to Present CUSTOM I, II Trial Data at TCT 2007

October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., director of Cardiology, University Medical Center, Utrecht, Netherlands, will present an historical overview and current perspective on the treatment of multivessel coronary disease and the treatment of long lesions. An overview of the Custom NX DES System with respect to the treatment of multivessel and diffuse disease will be discussed, along with the one-year follow-up results of the CUSTOM II Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington Convention Center
Event: Evening Symposium – Delivering Safety to Today’s Patients

Professor Eberhard Grube, M.D., chief of Cardiology at the HELIOS Heart Center in Siebgurg, Germany and principal investigator of the CUSTOM I and II clinical trials, will review the results to date from Biolimus A9 DES clinical trials and registries. Professor Grube will present two-year results from the CUSTOM I clinical trial and one-year results from the CUSTOM II clinical trial.

Bernard de Bruyne, M.D., Ph.D, Cardiovascular Center, OLV Hospital in Aalst, Belgium, will provide an overview of the Custom NX technology in a presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel, Grand Ballroom, 999 Ninth Street NW

Monday, October 22
Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

For more information: www.xtentinc.com

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init